This panel discussion will examine evolving trial data on functional and anatomic outcomes in geographic atrophy and analyze how targeting different components of the complement pathway may lead to distinct therapeutic outcomes.
This content was captured during a live-virtual symposium. Polling took place during the symposium.
This activity is supported by an independent medical education grant from Annexon Biosciences.
Upon completion of this activity, the participant should be able to:
Provided by Evolve Medical Education 
Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Evolve designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Roger A. Goldberg, MD, MBA
Vitreoretinal Specialist
Bay Area Retina Associates
Volunteer Faculty
California Pacific Medical Center
Walnut Creek, CA
Karl Csaky, MD, PhD
Chief Executive Medical Officer
Lab Director of the Molecular Ophthalmology Laboratory
Retina Foundation of the Southwest
Dallas, TX
Eleonora (Nora) Lad, MD, PhD
Vice Chair of Ophthalmology Clinical Research
Duke University Medical Center
Durham, NC
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
Roger A. Goldberg, MD, MBA, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AbbVie, Annexon Biosciences, Apellis Pharmaceuticals, Boehringer Ingelheim, Carl Zeiss Meditec, Coherus Biosciences, EyePoint Pharmaceuticals, Genentech/Roche, Outlook, and Regeneron. Grant/Research Support: Affamed, Annexon Biosciences, Apellis Pharmaceuticals, Boehringer Ingelheim, Carl Zeiss Meditec, EyePoint Pharmaceuticals, Genentech/Roche, Janssen, Neurotech, and Novo Nordisk. Speaker's Bureau: Apellis Pharmaceuticals, Biogen, and Genentech/Roche.
Karl Csaky, MD, PhD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AbbVie, Adverum Biothechnologies, Annexon Biosciences, EyeBio, Genentech, Heidelberg Engineering, Johnson & Johnson Vision, Merck, NGM Biopharmaceuticals, Novartis, Ocular Therapeutix, Regeneron, Ribomic, Roche, and TenPoint Therapeutics. Grant/Research Support: Annexon Biosciences, Genentech, Gyroscope Therapeutics, NGM Biopharmaceuticals, and Novartis. Speaker's Bureau: Genentech.
Eleonora (Nora) Lad, MD, PhD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: 4DMT, Alexion, Allegro Ophthalmics, Amaros Medical, Annexon Biosciences, Apellis Pharmaceuticals, Aspen Neuroscience, Blue Rock, Boehringer Ingelheim, Broadwing Bio, Galimedix, Gemini Pharmaceuticals, Iveric Bio, Janssen, Nanoscope Therapeutics, NGM Biopharmaceuticals, Novartis, Osanni Bio, Perceive Bio, Retrotope, Roche, Sanofi, and Théa Pharma. Grant/Research Support: Alexion, Apellis Pharmaceuticals, Belite Bio, Boehringer Ingelheim, Gemini Pharmaceuticals, Iveric Bio, Janssen, LumiThera, Neurotech Pharmaceuticals, NGM Biopharmaceuticals, Novartis, and Roche. Shareholder: Amaros Medical, Osanni Bio, and Retrotope. Provisional Patent: 63162741: "A SYSTEM AND METHOD TO PREDICT PROGRESSION OF AGE-RELATED MACULAR DEGENERATION".
The Evolve staff, planners and peer reviewer have no financial relationships with ineligible companies.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Annexon Biosciences.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Real-World Evidence of Photobiomodulation Efficacy in Ocular Indications
1.00 program credit
Marion Munk, MD, Ph.D
David Boyer, MD
Diana V. Do, MD
David Boyer, MD
David Boyer, MD
Diana V. Do, MD
Marion Munk, MD, Ph.D
David Boyer, MD
